Deerfield Management Company L.P. Series C bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 155,759 shares of the company’s stock, valued at approximately $869,000.
Other institutional investors also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Cytek Biosciences by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 880,038 shares of the company’s stock valued at $8,026,000 after purchasing an additional 44,345 shares in the last quarter. Teachers Retirement System of The State of Kentucky grew its holdings in Cytek Biosciences by 16.8% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 116,937 shares of the company’s stock worth $1,067,000 after acquiring an additional 16,804 shares during the last quarter. Vanguard Group Inc. increased its position in Cytek Biosciences by 7.3% in the 4th quarter. Vanguard Group Inc. now owns 11,890,700 shares of the company’s stock valued at $108,443,000 after acquiring an additional 811,279 shares during the period. Cornerstone Investment Partners LLC acquired a new position in shares of Cytek Biosciences during the first quarter worth $171,000. Finally, Texas Permanent School Fund Corp grew its stake in shares of Cytek Biosciences by 2.0% in the first quarter. Texas Permanent School Fund Corp now owns 86,601 shares of the company’s stock worth $581,000 after purchasing an additional 1,702 shares during the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.
Cytek Biosciences Price Performance
CTKB opened at $5.20 on Friday. Cytek Biosciences, Inc. has a 1 year low of $3.80 and a 1 year high of $9.87. The company has a market capitalization of $682.62 million, a price-to-earnings ratio of -57.78 and a beta of 1.31. The firm’s fifty day moving average price is $5.59 and its two-hundred day moving average price is $5.93.
Wall Street Analysts Forecast Growth
Separately, Piper Sandler cut their target price on Cytek Biosciences from $8.50 to $8.00 and set an “overweight” rating on the stock in a report on Tuesday, August 13th.
Check Out Our Latest Analysis on Cytek Biosciences
Cytek Biosciences Company Profile
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Further Reading
- Five stocks we like better than Cytek Biosciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Health Care Stocks Explained: Why You Might Want to Invest
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding CTKB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytek Biosciences, Inc. (NASDAQ:CTKB – Free Report).
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.